Oncotelic Therapeutics, Inc. (OTCQB: OTLC) was featured in a NetworkNewsAudio editorial that highlighted the company's efforts to overcome the blood-brain barrier, a major challenge in central nervous system (CNS) drug delivery. The editorial emphasized the significant unmet medical need for effective treatments for CNS disorders and the potential of Oncotelic's proprietary technologies to address this gap.
According to the editorial, Oncotelic has been advancing its N2B delivery system, a technology designed to facilitate the transport of therapeutic agents across the blood-brain barrier. This system is central to the company's recent strategic monetization agreement with Lunai Bioworks, which aims to support initiatives in biodefense and Alzheimer's disease treatment. The partnership underscores the versatility of the N2B platform and its potential applications beyond oncology.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Additionally, Oncotelic leverages its proprietary AI-enabled PDAOAI platform to enhance research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic's position in oncology and rare disease therapeutics.
The full press release is available at https://nnw.fm/kxGyR. For the latest news and updates relating to OTLC, visit the company's newsroom at https://nnw.fm/OTLC.
